Europe Heparin Market Is Estimated To Account For US$ 4,085.8 Million By 2027 at a CAGR of 6.1% between 2020 and 2027 | Coherent Market Insights

SEATTLE, May 04, 2021, (PHARMIWEB) — 

Heparin is administered intravenously, and unfractionated heparin (UFH) has a half-life of one to two hours. Low-molecular-weight heparin (LMWH) has a half-life of four to eight hours. Heparin is made either naturally or synthetically from mucosal tissues of slaughtered meat animals such as porcine intestines or bovine lungs.

Rising cases of venous thromboembolism (VTE) is expected to boost the growth of the Europe heparin market over the forecast period. From 2008 to 2017, 75,846 people were admitted to hospital in Scotland for VTE, according to NHS Scotland’s 2018 study.

Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/3960

Restraints:

The risk of thrombocytopenia caused by heparin is expected to restrict market growth. Heparin-induced thrombocytopenia (HIT) is a heparin-related complication. Forms 1 and 2 HIT are the two types of HIT. Within two days of starting heparin therapy, type 1 HIT develops, while type 2 develops after four to ten days.

In terms of value, the Low Molecular Weight Heparin segment dominated the European heparin market in 2019, accounting for 81.4 percent of the market, led by Ultra Low Molecular Weight Heparin. The market is expected to grow in the near future due to the increasing demand for Low Molecular Weight Heparin in the reduction of lung injury.

Market Trends:

Rising cases of chronic kidney disease is driving the growth of the market. According to a report published in February 2020 titled ‘Prevalence and deaths for chronic kidney disease in 2017, and percentage change of age-standardized rates by location, 1990–2017,’ the United Kingdom had about 5,636,676 cases of chronic kidney disease in 2017.

Key players in the market are sourcing active pharmaceutical ingredients from Europe. For instance, Preservative-free Heparin Sodium Injection, USP in 5,000 USP units per 0.5 mL in Simplist ready-to-administer prefilled syringes were introduced in November 2019 by Fresenius Kabi in the United States. The active pharmaceutical ingredient in the medication originates in Europe.

Competitive Landscape:

Major players operating in the Europe heparin market include Dr. Reddy’s Laboratories Ltd., Fresenius SE & Co. KGaA, Leap Labchem Co., LEO Pharma A/S, Sanofi S.A., Syntex S.A., Pfizer, Inc., Sagent Pharmaceuticals, Inc., B. Braun Melsungen AG, Baxter International Inc., GlaxoSmithKline plc, Bayer AG, Anselm Pharmaceuticals, Bristol-Myers Squibb Co., Teva Pharmaceutical Industries Ltd., United Biotech (P) Ltd, Amphastar Pharmaceuticals Inc., Abbott Laboratories, Aspen Pharmacare Holdings, Laboratorios Farmaceuticos ROVI SA, and Intrapharm Laboratories.

Buy This Complete A Business Report: https://www.coherentmarketinsights.com/insight/buy-now/3960

Detailed Segmentation:

Europe Heparin Market, By Product Type:

• • Low Molecular Weight Heparin
  • Unfractionated Heparin
  • Ultra Low Molecular Weight Heparin

Europe Heparin Market, By End User:

• • Hospitals
  • Blood and Stem Cell Bank
  • Others (Laboratories, Acute Care Centers)

View Press Release For More Information @ 

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contacts US:

Mr. Shah
Coherent Market Insights,
1001 4th Ave,
#3200 Seattle, WA 98154, U.S.
Phone: US +1-206-701-6702/UK +44-020 8133 4027
Email: sales@coherentmarketinsights.com